X4 Pharmaceuticals (Nasdaq: XFOR) granted inducement equity awards to new employees effective August 31, 2026 under its 2019 Inducement Equity Incentive Plan. According to X4 Pharmaceuticals, the awards are stock options to purchase an aggregate of 50,000 common shares at an exercise price of $4.04, equal to the closing price on the grant date, with a ten-year term.
Each option vests over four years: 25% after 12 months and the remainder monthly over the next 36 months, subject to continued employment. The grants were approved by the board’s Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). X4 is also advancing mavorixafor (XOLREMDI) for rare hematology diseases, including a global Phase 3 4WARD trial in chronic neutropenic disorders.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The platform record shows XFOR's inducement-grant precedents ranged from -1.7% to 4.89% over 24 hour...
Analysis
The platform record shows XFOR's inducement-grant precedents ranged from -1.7% to 4.89% over 24 hours. Current data also showed Net Selling and low short positioning, leaving insider activity and financing context as relevant considerations.
Key Figures
Grant Effective Date:August 31, 2026Option Shares:50,000 sharesOption Term:10 years+4 more
7 metrics
Grant Effective DateAugust 31, 2026Inducement awards
Option Shares50,000 sharesAggregate common-stock options granted to new employees
Option Term10 yearsInducement options
Exercise Price$4.04 per shareEqual to the August 31, 2026 closing price
Vesting Period4 yearsSubject to continued employment
Initial Vesting25%Shares vest after 12 months
Remaining Vesting36 monthsMonthly vesting after the initial 12-month period
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
cxcr4 antagonistmedical
"mavorixafor, an orally available CXCR4 antagonist"
A CXCR4 antagonist is a medicine that blocks a specific cell surface receptor called CXCR4, stopping signals that guide cell movement and survival. Think of it like putting a padlock on a door that cancer cells or immune cells use to travel and hide; this can slow tumor spread, help release stem cells for transplant, or interfere with viruses. For investors, drugs using this mechanism can create clear clinical milestones, niche market opportunities, and regulatory risks tied to trial results.
phase 3 clinical trialmedical
"conducting a global, pivotal Phase 3 clinical trial"
A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.
fast track designationregulatory
"FDA has granted Fast Track designation to mavorixafor"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 50,000 shares of X4’s common stock.These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of $4.04 per share, which is equal to the closing price of X4’s common stock on August 31, 2026.Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
What inducement grants did X4 Pharmaceuticals (XFOR) announce on September 1, 2026?
X4 Pharmaceuticals announced inducement stock option grants covering 50,000 shares of common stock for new employees. According to X4 Pharmaceuticals, these options were issued under the 2019 Inducement Equity Incentive Plan as material inducements to employment, consistent with Nasdaq Listing Rule 5635(c)(4).
What are the key terms of the new X4 Pharmaceuticals (XFOR) inducement stock options?
The inducement options have a ten-year term and a $4.04 exercise price per share. According to X4 Pharmaceuticals, each grant vests over four years, with 25% after 12 months and the remaining 75% vesting monthly over the subsequent 36 months, subject to continued employment.
How do the X4 Pharmaceuticals (XFOR) inducement options vest for new employees?
Each inducement option vests over a four-year schedule tied to continued employment at X4. According to X4 Pharmaceuticals, 25% of the shares vest after 12 months, and the remaining 75% vest in equal monthly installments during the following 36 months.
Under which plan and Nasdaq rule were the X4 Pharmaceuticals (XFOR) inducement awards granted?
The inducement awards were granted under the 2019 Inducement Equity Incentive Plan and Nasdaq Rule 5635(c)(4). According to X4 Pharmaceuticals, this plan is used exclusively for equity awards to individuals not previously employed by the company, as material inducements to joining.
What is X4 Pharmaceuticals’ lead therapy mavorixafor (XOLREMDI) mentioned in the XFOR inducement grant news?
Mavorixafor, branded as XOLREMDI, is an orally available CXCR4 antagonist for WHIM syndrome. According to X4 Pharmaceuticals, it is approved in the U.S. and EU, and is being studied in the global Phase 3 4WARD trial in chronic neutropenic disorders.
What clinical program is X4 Pharmaceuticals (XFOR) running alongside its September 2026 inducement grants?
X4 is conducting the global, pivotal Phase 3 4WARD trial evaluating mavorixafor in chronic neutropenic disorders. According to X4 Pharmaceuticals, the U.S. FDA has granted Fast Track designation to mavorixafor for treating chronic neutropenia, reflecting regulatory support for its development.
